How Is Hematogenous Disseminated Tuberculosis Diagnosed?

Diagnosing hematogenous disseminated tuberculosis—commonly referred to as miliary tuberculosis—requires a high index of clinical suspicion, especially in immunocompromised individuals or those with nonspecific systemic symptoms such as prolonged fever, night sweats, weight loss, and fatigue. Because the disease results from widespread hematogenous seeding of Mycobacterium tuberculosis, imaging and microbiological confirmation are critical.

Chest radiography often serves as the initial imaging modality; however, it may appear normal early in the disease or show subtle, diffuse micronodules—typically 1–3 mm in diameter—distributed uniformly throughout both lung fields, resembling millet seeds (hence the term “miliary”). High-resolution computed tomography (HRCT) is significantly more sensitive and frequently reveals innumerable small, well-defined nodules with a predilection for the upper lobes and perilymphatic distribution—findings highly suggestive of miliary TB when correlated clinically.

Microbiological diagnosis remains the gold standard. Sputum samples—ideally collected on three consecutive mornings—should undergo acid-fast bacilli (AFB) smear microscopy, mycobacterial culture, and nucleic acid amplification testing (NAAT), such as Xpert MTB/RIF or Ultra assays. In cases where sputum is unavailable or nonproductive, bronchoalveolar lavage (BAL) fluid or induced sputum can be used. Blood cultures using mycobacterial-specific media (e.g., Myco/F Lytic bottles) have modest sensitivity but may yield positive results in advanced or immunosuppressed cases.

Extrapulmonary involvement is common and warrants targeted evaluation: cerebrospinal fluid (CSF) analysis in patients with neurological symptoms (showing lymphocytic pleocytosis, elevated protein, low glucose, and positive AFB smear/culture/NAAT); liver function tests and abdominal ultrasound if hepatic involvement is suspected; and ophthalmologic examination for choroidal tubercles, which may be detected even in asymptomatic patients.

Interferon-gamma release assays (IGRAs) or tuberculin skin testing (TST) support latent TB infection but cannot differentiate active disease and thus serve only as adjunctive tools. Histopathological examination of biopsy specimens—such as from bone marrow, lymph nodes, or liver—may demonstrate noncaseating or caseating granulomas with or without identifiable acid-fast bacilli, further supporting the diagnosis when microbiological results are inconclusive.